Highlights 9 Meters Biopharma, Inc.

Equities

NMTRQ

US6544052086

Market Closed - OTC Markets Other stock markets 13:27:18 2024-06-26 EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

03-25	North American Morning Briefing : Tech in Focus on -2-	DJ
2023	Bidding Procedure Approved for 9 Meters Biopharma, Inc.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech	23-08-25	DJ
Illumina cuts annual profit forecast as biotech funding woes linger	23-08-09	RE
Illumina cuts annual profit forecast	23-08-09	RE
9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome	23-05-30	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
9 Meters Biopharma, Inc. Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity	23-04-05	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome	22-11-29	CI
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy	22-11-14	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
9 Meters Biopharma Launching 1-for-20 Reverse Stock Split; Shares Drop	22-10-17	MT
9 Meters Biopharma Reports Positive Final Results in Short Bowel Syndrome Trial; Shares Jumps After Hours	22-09-26	MT
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome	22-09-26	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome	22-06-30	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
North American Morning Briefing : Tech Futures -2-	22-05-13	DJ
9 Meters Biopharma, Inc. Enters into an Exclusive License Agreement with EBRIS Srl	22-04-13	CI
9 Meters Biopharma Says Patent Application Allowed for NM-136 to Treat Certain Metabolic Disorders	22-04-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 9 Meters Biopharma, Inc.

Equities

NMTRQ

US6544052086

Highlights

Filters